Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: The NCIC Clinical Trials Group and AGITG CO.20 trial

Journal of Clinical Oncology

Volumn 31, Issue 19, 2013, Pages 2477-2484

  Siu, Lillian L ^a   Shapiro, Jeremy D ^h   Jonker, Derek J ^b   Karapetis, Chris S ^k   Zalcberg, John R ⁱ   Simes, John ^m   Couture, Felix ^d   Moore, Malcolm J ^a   Price, Timothy J ^l   Siddiqui, Jehan ^f   Nott, Louise M ^o   Charpentier, Danielle ^e   Liauw, Winston ⁿ   Sawyer, Michael B ^g   Jefford, Michael ⁱ   Magoski, Nadine M ^c   Haydon, Andrew ^j   Walters, Ian ^p   Ringash, Jolie ^a   Tu, Dongsheng ^c   O'Callaghan, Chris J ^c   more..

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c QUEEN S UNIVERSITY   (Canada)

^d LAVAL UNIVERSITY   (Canada)

^e NOTRE DAME HOSPITAL   (Canada)

^f Dr H Bliss Murphy Cancer Centre   (Canada)

^g CROSS CANCER INSTITUTE   (Canada)

^h MONASH UNIVERSITY   (Australia)

ⁱ UNIVERSITY OF MELBOURNE   (Australia)

^j ALFRED HOSPITAL   (Australia)

^k FLINDERS UNIVERSITY   (Australia)

^l UNIVERSITY OF ADELAIDE   (Australia)

^m UNIVERSITY OF SYDNEY   (Australia)

ⁿ UNIVERSITY OF NEW SOUTH WALES   (Australia)

^o ROYAL HOBART HOSPITAL   (Australia)

^p BRISTOL MYERS SQUIBB   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; BRIVANIB ALANINATE; CAPECITABINE; CETUXIMAB; FLUOROURACIL; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; PLACEBO; ALANINE; ANTINEOPLASTIC AGENT; BRIVANIB; DRUG DERIVATIVE; MONOCLONAL ANTIBODY; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; TRIAZINE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN TISSUE; INTENTION TO TREAT ANALYSIS; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; ONCOGENE K RAS; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; REFRACTORY PERIOD; TISSUE SECTION; UNSPECIFIED SIDE EFFECT; VERY ELDERLY; WILD TYPE; CARCINOMA; COLORECTAL TUMOR; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; DRUG ANTAGONISM; DRUG RESISTANCE; GENETICS; KAPLAN MEIER METHOD; METASTASIS; MIDDLE AGED; MULTICENTER STUDY; ONCOGENE RAS; PATHOLOGY; RISK; TREATMENT FAILURE;

ADULT; AGED; ALANINE; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; GENES, RAS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; ODDS RATIO; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; TREATMENT FAILURE; TRIAZINES;

EID: 84883074556     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.46.0543     Document Type: Article

References (21)

1. Karapetis CS, Khambata-Ford S, Jonker DJ, et al: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757-1765, 2008
2. Amado RG, Wolf M, Peeters M, et al: Wildtype KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626-1634, 2008
3. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al: Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040-2048, 2007
4. Diaz-Padilla I, Siu LL: Brivanib alaninate for cancer. Expert Opin Investig Drugs 20:577-586, 2011
5. Tol J, Koopman M, Cats A, et al: Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360:563-572, 2009
6. Hecht JR, Mitchell E, Chidiac T, et al: A randomized phase IIIB trial of chemotherapy, be-vacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for meta-static colorectal cancer. J Clin Oncol 27:672-680, 2009
7. Saltz L, Badarinath S, Dakhil S, et al: Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer. Clin Colorectal Cancer 11:101-111, 2012
8. Saltz LB, Lenz HJ, Kindler HL, et al: Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: The BOND-2 study. J Clin Oncol 25:4557-4561, 2007
9. Casanovas O, Hicklin DJ, Bergers G, et al: Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8:299-309, 2005
10. Kopetz S, Hoff PM, Morris JS, et al: Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: Efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol 28:453-459, 2010
11. Garrett CR, Siu LL, El-Khoueiry A, et al: Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy. Br J Cancer 105:44-52, 2011
12. Ayers M, Awad M, Malone D, et al: Correlation between K-ras status and efficacy results from a phase I/II study of brivanib alaninate in combination with cetuximab in patients (pts) with advanced or metastatic colorectal cancer (CRC). 2009 Gastrointestinal Cancers Symposium, San Francisco, CA, January 15-17, 2009 (abstr 375)
13. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
14. Pocock SJ, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31:103-115, 1975
15. Klein JP, Moeschberger ML: Survival Analysis: Techniques for Censored and Truncated Data. New York, NY, Springer, 1997
16. Fracasso PM, Burris H 3rd, Arquette MA, et al: A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: Pharmacokinetic and pharmacodynamic rationale for dosing. Clin Cancer Res 13:986-993, 2007
17. Hecht JR, Trarbach T, Hainsworth JD, et al: Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma. J Clin Oncol 29:1997-2003, 2011
18. Van Cutsem E, Bajetta E, Valle J, et al: Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma. J Clin Oncol 29:2004-2010, 2011
19. Schmoll H, Cunningham D, Sobrero A, et al: mFOLFOX6 + cediranib vs mFOLFOX6 + bevacizumab in previously untreated metastatic colorectal cancer (mCRC): A randomized, double-blind, phase I/III study (HORIZON III). Ann Oncol 21:viii189-viii224, 2010 (suppl 8; abstr 580O)
20. Grothey A, Van Cutsem E, Sobrero A, et al: Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebocontrolled, phase 3 trial. Lancet 381:303-312, 2013
21. Jain RK, Duda DG, Clark JW, et al: Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 3:24-40, 2006